Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $55 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts HRMY Hot Sheet
Price: $36.13 +0.28%
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $55.00 (from $43.00) while maintaining a Buy rating.
You May Also Be Interested In
- Mizuhoon Harmony Biosciences (HRMY): 'we recommend being opportunistic on yesterday's share weakness'
- Tango Therapeutics Inc. (TNGX) PT Raised to $45 at Wedbush
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,460 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
